iinnovate-2
Phase 1 Terminated
15 enrolled 15 charts
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
36 enrolled 17 charts
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase 1/2 Terminated
32 enrolled 18 charts
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Phase 2 Terminated
1 enrolled 1 chart
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation
Phase 3 Terminated
269 enrolled 9 charts
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase 1/2 Terminated
46 enrolled 29 charts
Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Phase 2 Terminated
10 enrolled 37 charts
DMV
Phase 1/2 Terminated
13 enrolled 8 charts
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Phase 1/2 Terminated
83 enrolled 31 charts
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Phase 1/2 Terminated
6 enrolled 8 charts
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
Phase 1/2 Terminated
7 enrolled 9 charts
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Phase 2 Terminated
4 enrolled 6 charts
Trial of Romidepsin and Bortezomib for Multiple Myeloma
Phase 2 Terminated
32 enrolled 14 charts
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
Phase 2 Terminated
9 enrolled 2 charts
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Phase 2 Terminated
2 enrolled 11 charts
A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
32 enrolled 12 charts
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma
Phase 2 Terminated
24 enrolled 24 charts
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
Phase 1/2 Terminated
22 enrolled 21 charts
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
Phase 2 Terminated
23 enrolled 9 charts
VRCD
Phase 2 Terminated
12 enrolled 7 charts
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Phase 1/2 Terminated
19 enrolled 10 charts
VelRand
Phase 3 Terminated
3 enrolled 11 charts
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 6 charts
PANORAMA4
Phase 2 Terminated
6 enrolled 7 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase 2 Terminated
12 enrolled 10 charts
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 2 Terminated
16 enrolled 7 charts
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Phase 2 Terminated
7 enrolled 8 charts
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Terminated
2 enrolled 6 charts
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
Phase 3 Terminated
20 enrolled 7 charts
2007-77
Phase 3 Terminated
10 enrolled 5 charts
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Phase 1/2 Terminated
31 enrolled 10 charts
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
Phase 2 Terminated
20 enrolled 13 charts
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
Phase 2 Terminated
19 enrolled 7 charts
Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Phase 2 Terminated
17 enrolled 16 charts
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
Phase 2 Terminated
6 enrolled 8 charts
Safety Study of Dasatinib With Bortezomib (VelcadeĀ®) and Dexamethasone for Multiple Myeloma
Phase 1 Terminated
16 enrolled 15 charts
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 6 charts
Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Phase 2 Terminated
4 enrolled 7 charts
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Phase 2 Terminated
17 enrolled 5 charts
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Phase 2 Terminated
3 enrolled 4 charts
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
Phase 2 Terminated
17 enrolled 6 charts
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2 Terminated
5 enrolled 8 charts
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
Phase 3 Terminated
48 enrolled 9 charts
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
6 enrolled 4 charts
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 1/2 Terminated
3 enrolled 5 charts